GSK vs Sanofi - A Battle for Medical Breakthroughs and Global Healthcare Dominance: Ken Research

 Global Pharmaceutical leaders GSK and Sanofi competing for market share in vaccines, general healthcare with investments in R&D and new collaborations.

Storyline

• Sanofi, a global pharmaceutical company, has a strong market presence in therapeutic areas like diabetes, cardiovascular diseases, and vaccines. Sanofi Pasteur, its vaccines division, is a leading manufacturer worldwide.
• GSK, a British multinational, excels in respiratory health, HIV, vaccines, and consumer healthcare. GSK Vaccines is renowned for its vaccine offerings.
• Both companies heavily invest in R&D to innovate and develop new drugs and vaccines. Sanofi emphasizes partnerships, while GSK focuses on genetically identified and infectious disease targets.
• Strategic collaborations drive their growth strategies. Sanofi partners with Regeneron Pharmaceuticals and has a premium partnership for the Paris 2024 Olympic and Paralympic Games. GSK collaborates with organizations like the University of California and IDEAYA in areas like oncology.

Introduction

Sanofi and GSK are both global pharmaceutical companies engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products, including prescription medicines, vaccines, and consumer healthcare products.

1. Revenue and Market Presence:

Sanofi:

Sanofi is a French multinational pharmaceutical company with a significant global presence. It has a diverse portfolio of products across various therapeutic areas, including diabetes, cardiovascular diseases, vaccines, and rare diseases. Sanofi is one of the top pharmaceutical companies worldwide. It is headquartered in Paris, France. In 2022, influenza vaccines generated approximately three billion euros of revenue.

GSK:

GlaxoSmithKline, a British multinational pharmaceutical company, is also a major player in the global pharmaceutical industry. It operates in various segments such as pharmaceuticals, vaccines, and consumer healthcare. GSK has a strong presence in areas like respiratory health, HIV, vaccines, and consumer healthcare products. 

Product Portfolio:

Sanofi:

Sanofi's product portfolio includes branded prescription drugs such as Lantus (insulin), Dupixent (for atopic dermatitis and asthma), and Aubagio (for multiple sclerosis). Sanofi also has a significant presence in the vaccine market, including vaccines for influenza, meningococcal diseases, and paediatric diseases.

GSK:

GSK's product portfolio encompasses prescription medicines like Advair (for respiratory diseases), Augmentin (antibiotic), and Tivicay (for HIV). GSK has a strong focus on vaccines, including those for hepatitis, shingles, and influenza. Additionally, it offers a wide range of consumer healthcare products, including Sensodyne, Panadol, and Voltaren.

Vaccine Market:

Both Sanofi and GSK have notable expertise and market presence in the vaccine segment. However, their focus and capabilities may vary.

Sanofi

To learn more about this report Download a Free Sample Report 

Sanofi is known for its vaccines division, Sanofi Pasteur, which develops vaccines for various diseases, including influenza, dengue, polio, and meningitis. Sanofi Pasteur is one of the largest vaccine manufacturers globally.

GSK

Visit this Link: – Request for custom report 

GSK has a substantial presence in vaccines as well. It produces vaccines for diseases such as hepatitis, shingles, rotavirus, and meningitis. GSK's vaccine division is called GSK Vaccines.

Research and Development (R&D):

Both Sanofi and GSK invest significantly in research and development activities to discover and develop new drugs and vaccines.

Sanofi

Sanofi has multiple R&D centres globally, focusing on various therapeutic areas. It emphasizes partnerships and collaborations to enhance its R&D efforts. “We’ve identified conditions in immunology and inflammation as areas of great opportunity. The challenge of developing new treatments for conditions such as atopic dermatitis and asthma is just one of the many in which we believe AI can offer game-changing aid." said Generous-Marlin.

GSK

In 2022, GSK invested £5.5 Bn in R&D – 9% AER more than 2021 - to enhance GSK’s pipeline of vaccines and medicines and help us get ahead of disease together. GSK scientists prioritise genetically identified targets that are at least twice as likely to succeed in the clinic.  They also prioritise infectious disease targets and immune-modulators that have greater lifecycle opportunities.

Strategic Collaborations and Partnerships:

Both companies actively pursue strategic collaborations with other pharmaceutical firms, research institutions, and biotech companies to strengthen their pipelines and access new technologies. Sanofi has entered into various collaborations, such as its partnership with Regeneron Pharmaceuticals for the development of biologics, including Dupixent.

Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris.

"Sanofi is proud to contribute to the success of the Olympic and Paralympic Games Paris 2024. It represents a great opportunity to unite our employees around shared values with the Olympics and Paralympics, such as inclusion and diversity, openness to the world, courage, determination and excellence." Says Paul Hudson, Sanofi CEO. GSK has formed partnerships with multiple organizations, including the University of California, to explore novel therapies and approaches in areas like oncology and immunology.

IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology

It's important to note that the competitive landscape in the pharmaceutical industry can be dynamic, with mergers, acquisitions, and new product launches shaping the market.

According to Ken Research: Sanofi and GSK compete in various therapeutic areas, with diverse product portfolios and a focus on vaccines. They invest in R&D and form strategic collaborations to drive innovation. The dynamic nature of the pharmaceutical industry, characterized by mergers, acquisitions, and product launches, shapes their competitive landscape.

Vietnam's Collaborative Leap: Joining Forces with Pfizer, a Leading US Vaccine Developer: Ken Research

 Vietnam Aims for Collaborative Partnership with Pfizer Inc. to Enhance Medicine and Vaccine Supply, and Encourage Investment in Drug Production and Medical Biological Products

Storyline

• Vietnam's economic progress attracts Pfizer, leading to a partnership with Medochemie in the country's growing market.
• Pfizer shares advanced technology with Medochemie, enabling the production of around a dozen Pfizer medications, including sterile injectables.
• Medochemie, a Cyprus-based pharmaceutical company with established manufacturing sites in Vietnam, collaborates with Pfizer to tap into the country's expanding market.
• Through the alliance, Medochemie gains the capability to manufacture Pfizer medications, including sterile injectables, leveraging Vietnam's economic transformation.

Vietnam wishes to cooperate with Pfizer Inc., one of the world’s leading pharmaceutical and biotechnology companies, in medicine and vaccine supply, and hops it will invest in production of drugs, vaccines and medical biological products in the Southeast Asian nation in the near future, Deputy Minister of Health Do Xuan has said.

Introduction

Vietnam, a country that has made significant strides in its economic development, is now aiming for a collaborative partnership with Pfizer Inc., a renowned global pharmaceutical and biotechnology company. The objective is to enhance the supply of medicines and vaccines while encouraging Pfizer to invest in the production of drugs, vaccines, and medical biological products within the Southeast Asian nation.

1. Pfizer Teams Up with Medochemie to Expand Drug Manufacturing in Thriving Vietnamese Market.

To learn more about this report Download a Free Sample Report 

Medochemie, located in Cyprus, has three production locations in Vietnam and is acquiring Pfizer technology that will allow it to manufacture approximately a dozen Pfizer medications, including sterile injectables.

Vietnam's economy has progressed from one of the world’s lowest to one that is comfortably middle-income. Pfizer has taken notice and forged a collaboration to produce several of its products in the fast expanding Asian market.

The firm has reached an agreement with Medochemie, a Cyprus-based pharmaceutical company with three manufacturing facilities in Vietnam. Pfizer will transfer technology to Medochemie that will allow it to produce 11 Pfizer pharmaceuticals, including four sterile injectables and seven tablets.

Medochemie operates three factories in Vietnam:

• one for tablets and capsules,
• another for gels and creams,
• And a third for sterile injectables.

Visit this Link: –Request for custom report 

Pfizer did not disclose the amount of money that will be invested in the business, but the Vietnam Economic Times claims that Medochemie has committed $100 Mn in Vietnam to grow its locations. They have a total area of around 63,500 square metres and manufacture approximately 100 pharmaceuticals in the nation.

2. Pfizer Joins the Race, Enters the Country Following Competitors.

• In 2016, Sanofi struck a deal with VinaPharm to invest $75 Mn in a Sanofi manufacturing facility in Ho Chi Minh City to make prescription, generic and over-the-counter drugs.
• The same year, Japan's Taisho paid $97 Mn for a minority stake in Vietnamese firm DHG Pharma.
• Abbott bought Vietnamese manufacturer Glommed for an undisclosed sum, adding two local manufacturing facilities.

According to Ken Research: As Vietnam continues to attract foreign investments in its pharmaceutical industry, Pfizer's collaboration with Medochemie marks another significant milestone. With a focus on expanding medicine and vaccine supply, as well as promoting local drug production and medical biological products, Vietnam demonstrates its commitment to advancing healthcare capabilities. The partnership between Pfizer and Medochemie aligns with the country's vision of becoming a thriving hub for pharmaceutical innovation and accessibility in the Southeast Asian region.

4 Catalyst to growth in Vietnam Pharmaceutical Market: Ken Research

 Storyline

• Vietnam's growing affluent class and population of over 98 Mn have led to increased expenditure on medicines, reflecting a high paying capacity for healthcare.
• The country is undergoing a demographic shift, with an aging population expected to reach over 20% by 2038 and approximately 25% by 2049, further driving the demand for pharmaceutical drugs.
• The Vietnamese government has implemented proactive measures to enhance the healthcare system and pharmaceutical industry, including regulatory strengthening, streamlined drug registration processes, and support for domestic pharmaceutical production.
• Specialty drugs are in high demand due to the rising prevalence of chronic diseases like cancer and diabetes, offering targeted therapies and improved outcomes for patients amidst Vietnam's epidemiological transition.

Introduction

With a population of over 98 Mn and a growing affluent class, Vietnam's Expenditure on Medicines has risen significantly, showcasing its high paying capacity for healthcare. The country's aging population further contributes to the demand for pharmaceutical drugs. To address these needs, the Vietnamese government has implemented healthcare reforms and initiatives to boost domestic pharmaceutical production. Specialty drugs are sought after to combat the increasing prevalence of chronic diseases like cancer and diabetes, providing better outcomes for patients.

1. High Paying Capacity/Expenditure on medicines

Medicine And Vaccine Supply in Vietnam

Vietnam has a relatively large market size with a population of over 98 Mn and a life expectancy of approximately 76 years. Around 30% of the Vietnamese population that can afford relatively expensive western medicine is growing, equal to 30 Mn 2005, per capita drug spending was $9.85, in 2010 it was $22.25 and in 2019 it was $75. The average growth rate in the period 2010-2019 is 14.8%.

2. Increase in Aging Population in Vietnam

To learn more about this report Download a Free Sample Report 

According to the General Department of Population, Vietnam will become a country with an aging population by 2038 with the proportion of people aged 60 and over reaching over 20%. By 2049, the proportion of elderly people will account for about 25% of the population. With that, the demand for pharmaceutical drugs and medicines is only going to increase in the future.

3. Government Initiatives and Reforms

The Vietnamese government has implemented initiatives to improve the healthcare system and pharmaceutical industry. This includes measures to strengthen the regulatory framework, streamline drug registration processes, encourage domestic pharmaceutical production, and enhance intellectual property protection. These initiatives create a favorable environment for pharmaceutical companies to invest and expand their operations.

4. Growing Demand for Specialty Drugs

Visit this Link: – Request for custom report 

The cancer incidence rates for all cancers per 100,000 persons, which have been reported by the International Agency for Research on Cancer (IACR) in 2012, are 173 for males and 114.3 for females.

Therefore there is a dire need for speciality drugs in Vietnam which will cure diseases like cancer prevailing among the masses.

Mortality measures from sample-based surveillance: evidence of the epidemiological transition in Vietnam

According to Bull Health Organ, 2022

• Vietnam is experiencing an epidemiological transition, with a growing prevalence of chronic diseases such as cancer, diabetes, autoimmune disorders, and rare genetic conditions.
• Specialty drugs play a vital role in treating these complex diseases, offering targeted therapies and improved outcomes for patients.

According to Ken Research: Vietnam's high paying capacity, coupled with an increase in the aging population, has led to a surge in expenditure on medicines. The government's initiatives and reforms aim to strengthen the healthcare system and pharmaceutical industry, creating opportunities for growth and investment. The growing demand for specialty drugs reflects the rising prevalence of chronic diseases, particularly cancer, in the country. As Vietnam undergoes an epidemiological transition, the availability of targeted therapies and advanced treatment options becomes crucial for improving patient outcomes.